Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 7 pages · Chinese
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
- Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
- Announcement on Resolutions of the 19th Meeting of the 4th Board of Directors
- Announcement on Shareholding Reduction Plan of Shareholders
Later from Shanghai Junshi Biosciences
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Signing of an Authorization and License Agreement with Fosun Wanbang
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences